FDA Breast Implant Safety: What Changed and What It Means for You in 2026
The FDA has been tightening its grip on breast implant safety. If you have implants, or you are considering them, the regulatory landscape looks very different than it did five years ago.
Here is what has changed, what the data actually says, and what it means for your health decisions.
The Black Box Warning
In October 2021, the FDA required that all breast implant labeling include a boxed warning, the most serious type of warning the agency issues. This is the same category of warning used for medications with life-threatening risks.
The boxed warning states three things clearly:
Breast implants are not lifetime devices. The longer you have them, the greater your chance of developing complications, and some of those complications will require additional surgery.
Breast implants have been associated with a cancer of the immune system called BIA-ALCL (breast implant-associated anaplastic large cell lymphoma), which occurs more commonly with textured implants.
Breast implants have been associated with systemic symptoms in some women, a condition commonly known as breast implant illness (BII).
Before 2021, this information existed in the fine print. Now it is the first thing patients are supposed to see.
The Patient Decision Checklist
The FDA now requires implant manufacturers to include a patient decision checklist in their labeling. Surgeons must review this checklist with patients before surgery and both parties must initial and sign it.
The checklist covers situations where implants should not be used, what a suitable candidate looks like, the specific risks of the procedure (capsular contracture, rupture, infection, BII, BIA-ALCL), alternatives to implants (such as fat transfer), and the importance of choosing an appropriately trained surgeon.
For the first time, manufacturers must also disclose the specific materials used in their implants. Before this requirement, patients had no way to know exactly what was being placed inside their bodies.
The American Board of Cosmetic Surgery confirmed that these guidelines were designed to increase transparency and ensure informed consent. Whether individual surgeons actually follow through on reviewing the checklist thoroughly with each patient is another question, but the regulatory requirement is now on the books.
What the FDA Is Tracking: Systemic Symptoms
The FDA maintains a database of Medical Device Reports (MDRs) related to breast implants. As of the February 2025 update, the agency confirmed ongoing reports of systemic symptoms including:
- Fatigue
- Brain fog
- Joint pain
- Autoimmune-like symptoms
These are the same symptoms that the BII community has been reporting for years. The FDA's acknowledgment of these reports in its official safety communications is significant. It does not mean the FDA has classified BII as a formal diagnosis, but it does mean the agency considers the symptom reports serious enough to track and communicate publicly.
The Breast Implant Safety Alliance (BISA) noted that the February 2025 FDA update represents continued effort to ensure patient safety, informed decision-making, and industry accountability.
BIA-ALCL: The Cancer Risk
Since 2011, the FDA has tracked 1,380 cases of breast implant-associated anaplastic large cell lymphoma (BIA-ALCL), a rare cancer of the immune system. Sixty-four deaths have been linked to the condition, though incomplete reporting means the real number may be higher.
The median time from implant placement to BIA-ALCL diagnosis is 9 years, with a range of 1 to 22 years.
Eighty-six percent of reported cases were associated with Allergan textured implants. In July 2019, Allergan voluntarily recalled its BIOCELL textured breast implants and tissue expanders from the market. However, BIA-ALCL has been linked to all types of textured implants, not just Allergan's.
The FDA's position is that prophylactic removal of textured implants is not recommended in patients without symptoms. But the agency also says that individual patients should discuss the potential benefits and risks of removal with their healthcare providers.
In other words: if you have textured implants and you are not experiencing symptoms, the FDA is not telling you to run to the surgeon. But if you are experiencing symptoms, or if the risk concerns you, a conversation with your doctor is warranted.
Smooth implants are more common in the United States and are not affected by the Allergan recall.
Screening Recommendations
The FDA updated its rupture screening guidelines as part of the 2021 changes. The agency now recommends periodic imaging (MRI or ultrasound) of silicone gel-filled breast implants to check for rupture, regardless of whether you have symptoms.
Previously, MRI was the only recommended screening method. The addition of ultrasound as an acceptable alternative is a practical change, since ultrasound is significantly less expensive and more widely available.
The specific screening schedule your surgeon recommends may vary based on your implant type and how long you have had them. But the general principle is straightforward: silicone implants can rupture silently (without obvious symptoms), and periodic imaging catches problems before they become bigger problems.
The Ongoing Research Gap
Despite the regulatory progress, there are still significant gaps in the data.
The FDA has noted that previous post-approval studies conducted by manufacturers made "inadequate progress." In response, the agency increased the number of ongoing studies that manufacturers are required to conduct.
The Aesthetic Society established a BII task force that is tracking new breast implant patients over more than 10 years, which is the kind of large-scale, long-term study that has been missing from the conversation.
A systematic review published in Aesthetic Plastic Surgery in August 2025 analyzed the existing body of BII research and confirmed that while explantation leads to symptom improvement in the majority of patients, the exact mechanisms behind BII remain unclear. Hypotheses include immune responses to silicone, microbial colonization (biofilm), and inflammatory reactions, but no single cause has been definitively identified.
We know more than we did five years ago. We do not know enough.
What This Means If You Have Implants Right Now
If you currently have breast implants and you feel fine, there is no reason to panic. The FDA is not recommending mass removal. But there are a few things worth doing:
Know what you have. Find out the manufacturer, type (silicone or saline), surface (smooth or textured), and date of implantation. If you do not have this information, your surgeon's office should have records. Knowing your implant details allows you to stay informed about any future recalls or safety updates specific to your device.
Get screened. If you have silicone implants, schedule periodic imaging as recommended by your surgeon. MRI or ultrasound. Silent ruptures are common and worth catching early.
Pay attention to your body. If you develop new symptoms, especially fatigue, brain fog, joint pain, rash, or autoimmune-like symptoms, do not dismiss them. Mention your implants to your doctor. Ask whether BII could be a factor.
Support your health proactively. Even without symptoms, your body is managing a foreign device. An anti-inflammatory diet, adequate sleep, and targeted nutritional support can reduce the burden on your immune system.
Dr. Kayte's Silicone Implant Support formula was designed for exactly this scenario: daily nutritional support for immune and collagen balance with gentle detoxification, for anyone living with silicone implants. It does not replace screening, medical advice, or the decision about whether to explant. It supports your body while you navigate those decisions.
The Bigger Picture
Ten years ago, the conversation around breast implant safety was dominated by two positions: implants are perfectly safe, or implants are dangerous. Neither was accurate.
What we have now is something more useful: data. The FDA is tracking systemic symptoms. Manufacturers are required to be transparent about materials and risks. Patients have access to more information than ever before through both official channels and community networks.
The black box warning, the decision checklist, the screening recommendations, the increased research requirements. None of these things existed before 2021. They exist now because patients spoke up, and the evidence backed them.
If you have implants, stay informed. If you are considering implants, read the decision checklist. And if something does not feel right in your body, trust that instinct enough to investigate.
Dr. Kayte's Silicone Implant Support provides daily nutritional support for anyone living with silicone implants. Learn more [here].
Sources:
- BISA Nonprofit. "FDA Releases New Updates on the Safety and Effectiveness of Breast Implants." https://bisanonprofit.org/blog/breast-implant-safety-alliance-bisa-fda-releases-new-updates-on-the-safety-and-effectiveness-of-breast-implants
- FORCE. "FDA Issues New Breast Implant Labeling Recommendations." https://www.facingourrisk.org/privacy-policy-legal/advocacy/fda-updates-breast-implant-labeling-recommendations-to-improve-patient-communication
- American Board of Cosmetic Surgery. "What You Need to Know About the New FDA Breast Implant Guidelines." https://www.americanboardcosmeticsurgery.org/news/new-fda-breast-implant-guidelines/
- FDA. "Labeling for Approved Breast Implants." https://www.fda.gov/medical-devices/breast-implants/labeling-approved-breast-implants
- FDA / CDRH. "CDRH's Continued Commitment to Breast Implant Safety." https://www.fda.gov/medical-devices/medical-devices-news-and-events/cdrh-statement-cdrhs-continued-commitment-breast-implant-safety
- Barros et al. "Breast Implant Illness: Symptoms, Outcomes with Explantation and Potential Etiologies." Aesthetic Plastic Surgery, Springer Nature. https://link.springer.com/article/10.1007/s00266-025-05142-x
- Anca Breahna Plastic Surgeon. "Breast Implant Illness - BII Update 2026." https://ancabreahna.com/blog/breast-implant-illness
